deltatrials
Not Yet Recruiting PHASE2 INTERVENTIONAL 2-arm NCT06295094

The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients. (EPICURE)

The Efficacy of Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC) Combined With CURativE Intent Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients. A Multicentre, Randomised, Open-label Phase-II Study

Sponsor: Karolinska University Hospital

Conditions Chemotherapy, Adjuvant Gastric Cancer Minimally Invasive Surgical Procedures Peritoneal Metastases
Interventions Cisplatin Doxorubicin
Updated 3 times since 2024 Last updated: Mar 5, 2024 Started: Sep 30, 2024 Primary completion: Jan 31, 2027 Completion: Jan 31, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06295094, this PHASE2 trial focuses on Chemotherapy, Adjuvant and Gastric Cancer and remains actively recruiting participants. Sponsored by Karolinska University Hospital, it has been updated 3 times since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshotNot Yet Recruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshotNot Yet Recruiting

Change History

3 versions recorded

  1. Sep 2024 — Present [monthly]

    Not Yet Recruiting PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Not Yet Recruiting PHASE2

  3. Apr 2024 — Jul 2024 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Karolinska University Hospital
  • Odense University Hospital
Data source: Odense University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations